Cariprazine - Revision history

CategoryClaude: Sentence-case category link per house style (Mood_Stabilizers → Mood_stabilizers)

2026-05-23T05:02:21Z

Sentence-case category link per house style (Mood_Stabilizers → Mood_stabilizers)

← Older revision		Revision as of 05:02, 23 May 2026
Line 28:		Line 28:
	[[Category:Dopamine Partial Agonists]]		[[Category:Dopamine Partial Agonists]]
	[[Category:Psychotic Disorders]]		[[Category:Psychotic Disorders]]
	[[Category:Mood ~~Stabilizers~~]]		[[Category:Mood stabilizers]]

MDElliottMD: Category taxonomy (#23): retag to house-compliant neuroleptic categories

2026-05-22T14:41:19Z

Category taxonomy (#23): retag to house-compliant neuroleptic categories

← Older revision		Revision as of 14:41, 22 May 2026
Line 22:		Line 22:
	}}		}}

	[[Category:Second-~~Generation Antipsychotics (SGAs / Atypicals)~~]]		[[Category:Second-generation neuroleptics]]
	[[Category:Neuroleptics]]		[[Category:Neuroleptics]]
	[[Category:Third-~~Generation Antipsychotics~~]]		[[Category:Third-generation neuroleptics]]
	[[Category:Atypical Antipsychotics]]		[[Category:Atypical Antipsychotics]]
	~~[[Category:Antipsychotics]]~~
	[[Category:Dopamine Partial Agonists]]		[[Category:Dopamine Partial Agonists]]
	[[Category:Psychotic Disorders]]		[[Category:Psychotic Disorders]]
	[[Category:Mood Stabilizers]]		[[Category:Mood Stabilizers]]

MDElliottMD: Dedupe migration per interface-claude 2026-05-20: Antipsychotics / Neuroleptics merged into canonical Neuroleptics. Member retagged.

2026-05-19T18:00:16Z

Dedupe migration per interface-claude 2026-05-20: Antipsychotics / Neuroleptics merged into canonical Neuroleptics. Member retagged.

← Older revision		Revision as of 18:00, 19 May 2026
Line 22:		Line 22:
	}}		}}

	~~[[Category:Antipsychotics / Neuroleptics]]~~
	[[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]]		[[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]]
	[[Category:Neuroleptics]]		[[Category:Neuroleptics]]

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:05Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

← Older revision		Revision as of 03:16, 19 May 2026
Line 14:		Line 14:
	\| pregnancy = Limited data		\| pregnancy = Limited data
	\| legal = Rx		\| legal = Rx
	\| intro = '''Cariprazine''' (brand name Vraylar) is an atypical antipsychotic with a distinctive '''D3-preferring''' receptor profile — it has higher affinity for D3 than for D2, uncommon among antipsychotics. FDA-approved for schizophrenia (2015), bipolar mania (2015), bipolar depression (2019), and adjunctive treatment of major depressive disorder (2022). Stahl emphasizes the D3 partial agonism story for negative symptoms of schizophrenia and the mood-spectrum efficacy: postsynaptic D3 blockade in limbic regions reduces emotional dysregulation, while somatodendritic D3 effects in VTA disinhibit DA release in prefrontal cortex, addressing negative/cognitive/affective symptoms.		\| intro = '''Cariprazine''' (brand name Vraylar) is an atypical antipsychotic with a distinctive '''D3-preferring''' receptor profile, it has higher affinity for D3 than for D2, uncommon among antipsychotics. FDA-approved for schizophrenia (2015), bipolar mania (2015), bipolar depression (2019), and adjunctive treatment of major depressive disorder (2022). Stahl emphasizes the D3 partial agonism story for negative symptoms of schizophrenia and the mood-spectrum efficacy: postsynaptic D3 blockade in limbic regions reduces emotional dysregulation, while somatodendritic D3 effects in VTA disinhibit DA release in prefrontal cortex, addressing negative/cognitive/affective symptoms.

	Notable feature: very long-acting active metabolites (DCAR and DDCAR with half-lives up to 1-3 weeks), producing an 'oral depot' effect — missed doses cause less rapid decline in plasma levels than with shorter-acting agents.		Notable feature: very long-acting active metabolites (DCAR and DDCAR with half-lives up to 1-3 weeks), producing an 'oral depot' effect, missed doses cause less rapid decline in plasma levels than with shorter-acting agents.
	\| pharmacodynamics= D3 partial agonist (highest affinity); D2 partial agonist; 5HT1A partial agonist; 5HT2B antagonist; modest 5HT2A and H1 antagonism.		\| pharmacodynamics= D3 partial agonist (highest affinity); D2 partial agonist; 5HT1A partial agonist; 5HT2B antagonist; modest 5HT2A and H1 antagonism.
	\| effects = Akathisia (notable; reduced by slow titration), EPS, insomnia, sedation, nausea. Lower weight gain and metabolic effects than many atypicals. Long half-life of metabolites can delay both onset and offset of side effects.		\| effects = Akathisia (notable; reduced by slow titration), EPS, insomnia, sedation, nausea. Lower weight gain and metabolic effects than many atypicals. Long half-life of metabolites can delay both onset and offset of side effects.

Maintenance script: Expand Cariprazine with Stahl-sourced detail (with skepticism)

2026-05-16T02:03:46Z

Expand Cariprazine with Stahl-sourced detail (with skepticism)

← Older revision		Revision as of 02:03, 16 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	~~\| generic = Cariprazine~~		\| brand = Vraylar
	\| brand = Vraylar		\| classes = Atypical antipsychotic, D2/D3/5HT1A partial agonist
	~~\| structure =~~		\| mechanism = Partial agonist at D2 and D3 dopamine receptors with HIGHER affinity for D3 than D2 (uncommon among antipsychotics). Partial agonist at 5HT1A. Antagonist at 5HT2B. Weaker 5HT2A antagonism than other atypicals. The D3 partial agonism is proposed to drive efficacy for negative and cognitive symptoms of schizophrenia, and mood-related effects (depression in bipolar/MDD).
	\| classes = ~~Antipsychotic~~, ~~Neuroleptic~~		\| uses = Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022).
	\| mechanism = D3/D2 partial ~~agonist; 5~~-~~HT2A antagonist~~		\| starting_dose = Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg.
	\| uses =		\| preparations = 1.5 mg, 3 mg, 4.5 mg, 6 mg capsules
	\| starting_dose =		\| fda_max = 6 mg/d (psychosis/mania); 3 mg/d (depression adjunct)
	\| preparations =		\| routes = Oral
	\| fda_max =		\| onset = Weeks for psychosis/mood efficacy
	\| routes =		\| duration = Daily dosing; active metabolites with very long half-lives (up to 1-3 weeks)
	\| onset =		\| halflife = Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses
	\| duration =		\| bioavailability = Adequate oral bioavailability
	\| halflife =		\| pregnancy = Limited data
	\| bioavailability =		\| legal = Rx
	\| pregnancy =		\| intro = '''Cariprazine''' (brand name Vraylar) is an atypical antipsychotic with a distinctive '''D3-preferring''' receptor profile — it has higher affinity for D3 than for D2, uncommon among antipsychotics. FDA-approved for schizophrenia (2015), bipolar mania (2015), bipolar depression (2019), and adjunctive treatment of major depressive disorder (2022). Stahl emphasizes the D3 partial agonism story for negative symptoms of schizophrenia and the mood-spectrum efficacy: postsynaptic D3 blockade in limbic regions reduces emotional dysregulation, while somatodendritic D3 effects in VTA disinhibit DA release in prefrontal cortex, addressing negative/cognitive/affective symptoms.
	\| legal =
	\| intro =		Notable feature: very long-acting active metabolites (DCAR and DDCAR with half-lives up to 1-3 weeks), producing an 'oral depot' effect — missed doses cause less rapid decline in plasma levels than with shorter-acting agents.
	~~\| pharmacokinetics =~~		\| pharmacodynamics= D3 partial agonist (highest affinity); D2 partial agonist; 5HT1A partial agonist; 5HT2B antagonist; modest 5HT2A and H1 antagonism.
	\| pharmacodynamics =		\| effects = Akathisia (notable; reduced by slow titration), EPS, insomnia, sedation, nausea. Lower weight gain and metabolic effects than many atypicals. Long half-life of metabolites can delay both onset and offset of side effects.
	\| ~~indications~~ =		\| interactions = <pharmaInteractions/>
	~~\| dosing =~~
	\| effects =
	\| interactions = <pharmaInteractions/>
	~~\| pregnancy_details =~~
	~~\| monitoring =~~
	~~\| counseling =~~
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references =~~
	}}		}}


	[[Category:Antipsychotics / Neuroleptics]]		[[Category:Antipsychotics / Neuroleptics]]
Line 36:		Line 26:
	[[Category:Neuroleptics]]		[[Category:Neuroleptics]]
	[[Category:Third-Generation Antipsychotics]]		[[Category:Third-Generation Antipsychotics]]
			[[Category:Atypical Antipsychotics]]
			[[Category:Antipsychotics]]
			[[Category:Dopamine Partial Agonists]]
			[[Category:Psychotic Disorders]]
			[[Category:Mood Stabilizers]]

MDElliottMD: Comprehensive categorization: +Third-Generation Antipsychotics

2026-05-15T18:42:09Z

Comprehensive categorization: +Third-Generation Antipsychotics

← Older revision		Revision as of 18:42, 15 May 2026
Line 35:		Line 35:
	[[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]]		[[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]]
	[[Category:Neuroleptics]]		[[Category:Neuroleptics]]
			[[Category:Third-Generation Antipsychotics]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:06:51Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:06, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Antipsychotics / Neuroleptics]]
			[[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]]
	[[Category:Neuroleptics]]		[[Category:Neuroleptics]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:30:45Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:30, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:26Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:40Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Neuroleptics]]		[[Category:Neuroleptics]]